达沙替尼抑制基底B乳腺癌通过ETS1-介导的细胞外矩阵重塑
Xinyu Guo1,2, Heng Sun1,2,3, Feng Yu4
1Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, China.
Biomedicines
|December 30, 2025
概括
达沙替尼在治疗侵袭性三阴性乳腺癌 (TNBC),特别是基底B亚型的治疗中表现有前途. 这种药物通过向ETS原瘤基因1 (ETS1) 和矩阵金属蛋白酶-3 (MMP3) 来抑制癌细胞迁移和入侵.
科学领域:
- 在瘤学瘤学.
- 药物发现 药物发现 药物发现
- 癌症转移 癌症转移
背景情况:
- 三阴性乳腺癌 (TNBC),特别是基底B型,具有高度侵入性和转移性.
- 迫切需要对转移性TNBC进行有效的治疗.
- 了解TNBC的潜在机制对于开发向治疗至关重要.
研究的目的:
- 通过药物重用来确定转移性TNBC的有效治疗药物.
- 阐明潜在药物抑制TNBC入侵和转移的机制.
- 评估达沙替尼作为一种治疗性TNBC的治疗剂.
主要方法:
- 使用活细胞成像伤口愈合分析对140种FDA批准的药物的系统选.
- 通过体外入侵试验,体内模型和体外有机体培养来验证药物疗效.
- 对达沙替尼的分子机制的分析,包括对actin细胞骨,ETS1和MMP3表达的影响.
主要成果:
- 达沙替尼在侵袭性TNBC中表现出显著的抗癌活性,特别是基底B型,具有高ETS原型瘤基因1 (ETS1) 表达.
- 达沙替尼破坏了actin细胞骨架,降低了细胞运动性,并抑制ETS1和矩阵金属蛋白酶-3 (MMP3) 的表达,抑制了入侵.
- 达沙替尼与抗编程细胞死亡蛋白-1 (PD-1) 抗体的联合治疗显示出潜在的治疗效果.
结论:
- 达沙替尼是转移性TNBC的潜在治疗选择.
- 针对高ETS1表达的患者,可以优化达沙替尼治疗反应.
- 需要进一步研究组合疗法,包括使用PD-1抑制剂.
关键词:
排放系统原基因1 (ETS1) 排放系统原基因1 (ETS1)达萨提尼布 (dasatinib) 是一种细胞外矩阵是细胞外矩阵.矩阵金属蛋白酶-3 (MMP3) 的使用.转移 转移 转移 转移三重阴性乳腺癌 (TNBC) 是一种更多相关视频
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
14.1K
08:48An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
Published on: June 30, 2015
8.6K
相关概念视频
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
The JAK-STAT Signaling Pathway
11.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.8K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Intracellular Signaling Affects Focal Adhesions
3.4K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
3.4K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
PI3K/mTOR/AKT Signaling Pathway
5.2K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.2K
